Bilastine in the treatment of allergic rhinitis: separating facts from prejudice | Український Медичний Часопис

Bilastine, a 2nd generation antihistamine, is indicated for the treatment of allergic rhinitis, allergic rhinoconjunctivitis and chronic urticaria. Bilastine is not metabolised in the liver or kidneys, has a favorable safety and tolerability profile, and is free of sedative, adverse cerebral and cardiotoxic effects. Among the modern H1-blockers, bilastatin best meets the EAACI/ARIA criteria for an optimal antihistamine for the treatment of allergic rhinitis. The provisions of the international Delphi consensus reveal the advantages of using the original bilastine in patients with allergic rhinitis, allergic rhinoconjunctivitis and emphasise of its widespread clinical use.

References

1. Abdelshafy A.M., Abdallah S.Y., Hassan A. et al. (2022) The Impact of Bilastine on Symptoms of Allergic Rhinitis and Chronic Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am. J. Rhinol. Allergy, 36(5): 684–694. doi: 10.1177/19458924221097449.
2. Canonica G.W., Kuna P., Maurer M. et al. (2024) Delphi Study Group. Bilastine for the treatment of allergic rhinoconjunctivitis and urticaria: results from an international Delphi study. Drugs Context. 13: 2024-2-3. doi: 10.7573/dic.2024-2-3.
3. Ivancevich J.C., Cardona V., Larenas-Linnemann D. et al. (2019) Resumen ejecutivo de ARIA 2019: Vías integradas de atención para la rinitis alérgica en Argentina, España y México [Executive Summary of ARIA 2019: Integrated care pathways for allergic rhinitis in Argentina, Spain and Mexico]. Rev Alerg Mex., 66(4): 409–425. Spanish. doi: 10.29262/ram.v66i4.643.
4. Jáuregui I., Ramaekers J.G., Yanai K. et al. (2016) Bilastine: a new antihistamine with an optimal benefit-to-risk ratio for safety during driving. Expert Opin. Drug Saf., 15(1): 89–98. doi: 10.1517/14740338.2016.1112786.
5. Kawauchi H., Yanai K., Wang D. et al. (2019) Antihistamines for Allergic Rhinitis Treatment from the Viewpoint of Nonsedative Properties. Int. J. Mol. Sci., 20(1): 213. doi: 10.3390/ijms20010213.
6. Majorek-Olechowska B., Slomskis T., Zollerová L. et al. (2024) Pharmacokinetics and Safety of Bilastine 10 mg/d in Children Aged 2 to 5 Years With Allergic Rhinoconjunctivitis or Urticaria: A Phase 3 Clinical Trial. J. Investig. Allergol. Clin. Immunol. doi: 10.18176/jiaci.1003.
7. Narayanan V. (2019) Drug Profile: Bilastine. The Indian practitioner. http://www.researchgate.net/publication/333340644.
8. Simons F.E., Simons K.J. (2011) Histamine and H1-antihistamines: celebrating a century of progress. J. Allergy Clin. Immunol., 128(6): 1139–1150.e4. doi: 10.1016/j.jaci.2011.09.005.
9. Singh Randhawa A., Noor N., Md Daud M. et al. (2022) Efficacy and Safety of Bilastine in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis. Front. Pharmacol., 12: 731201. doi: 10.3389/fphar.2021.731201.
10. Tiwaskar M., Vora A., Tewary K. et al. (2023) Role of Bilastine in Allergic Rhinitis: A Narrative Review. J. Assoc. Physicians India, 71(11): 58–61. doi: 10.59556/japi.71.0401.
11. Yanai K., Rogala B., Chugh K. et al. (2012) Safety considerations in the management of allergic diseases: focus on antihistamines. Curr. Med. Res. Opin., 28(4): 623–642. doi: 10.1185/03007995.2012.672405.
12. Биластин в терапии аллергических заболеваний: инновации без границ (2018) Здоров’я України, 3(44).
13. Інструкція для застосування препарату Ніксар (2024). compendium.com.ua/info/220387/niksar/.